Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 22, 2015 5:09 PM ET

Pharmaceuticals

Company Overview of Emmaus Life Sciences, Inc.

Company Overview

Emmaus Life Sciences, Inc. is engaged in the discovery, development, and commercialization of treatments and therapies for rare and orphan diseases. The company’s lead product candidate includes pharmaceutical-grade L-glutamine, which has completed Phase III clinical trials for the treatment of sickle cell disease. It also markets and sells NutreStore, an L-glutamine powder for oral solution as a treatment for short bowel syndrome in patients receiving specialized nutritional support; and sells L-glutamine as a nutritional supplement under the AminoPure brand name through retail stores in various states, as well as through importers and distributors in Japan, Taiwan, and South Korea. The com...

20725 South Western Avenue

Suite 136

Torrance, CA 90501

United States

Founded in 2000

17 Employees

Phone:

310-214-0065

Key Executives for Emmaus Life Sciences, Inc.

Chief Financial Officer and Executive Vice President
Age: 59
Chief Operating Officer and Director
Age: 54
Senior Vice President of Finance
Age: 47
Senior Vice President of Research and Development
Age: 59
Chief Administrative Officer, Corporate Secretary and Director
Age: 38
Compensation as of Fiscal Year 2014.

Emmaus Life Sciences, Inc. Key Developments

Emmaus Life Sciences, Inc. announced delayed 10-Q filing

On 05/18/2015, Emmaus Life Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.

Emmaus Life Sciences, Inc. Announces Board Changes

Emmaus Life Sciences, Inc. announced that Tracey C. Doi voluntarily tendered her resignation from the board of directors of the company, effective immediately. Prior to her resignation, Ms. Doi served on the company's audit committee and compensation, nominating and corporate governance committee. She resigned due to disagreement with the company's senior management over business matters and cited her belief that she is no longer in a position to contribute meaningfully to the company and its shareholders. The company also announced that Akiko Moni Miyashita voluntarily tendered her resignation from the board, effective immediately. Prior to her resignation, Ms. Miyashita served on the company's audit committee and compensation, nominating and corporate governance committee. She resigned due to disagreement with the company's senior leadership team over strategy and cited her belief that she is unable to contribute meaningfully to the company and its shareholders.

Emmaus Life Sciences, Inc. Approves Amendments to By-Laws

Emmaus Life Sciences, Inc. announced that on April 24, 2015, written consents of the stockholders of the company purporting to take the following actions was delivered to the company: amend the company's by-laws to expressly provide that the advance notice provisions of the company's by-laws shall not apply in respect of any nominees for director elected by consent in lieu of a meeting of the stockholders under Section 228 of the Delaware General Corporation Law; amend the company's by-laws to provide that, unless and until the number of directors of the Board is increased or decreased by action of the stockholders or the Board, the total number of directors of the company will be 14; amend the company's by-laws to provide that any director vacancy or newly created directorship may also be filled by the stockholders of the company.

Similar Private Companies By Industry

Company Name Region
FidoPharm, Inc. United States
Health Maintenance Programs, Inc. United States
Vtesse, Inc. United States
Jason Properties, LLC United States
Rapidscan Pharma Solutions, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
April 13, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Emmaus Life Sciences, Inc., please visit www.emmausmedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.